Skip to main content
رجوع
OCUL logo

Ocular Therapeutix, Inc.

جودة البيانات: 100%
OCUL
NASDAQ Healthcare Biotechnology
KWD 8.33
▲ KWD 0.23 (2.84%)
القيمة السوقية: 1.81B
نطاق اليوم
KWD 8.18 KWD 8.44
نطاق 52 أسبوعًا
KWD 5.80 KWD 16.44
حجم التداول
3,471,749
متوسط 50 يوم / 200 يوم
KWD 9.58 / KWD 11.13
الإغلاق السابق
KWD 8.10

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -6.8 0.2
P/B 2.8 3.0
ROE % -54.9 3.6
Net Margin % -513.2 3.8
Rev Growth 5Y % 4.5 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 27.00 +224.1%
Low: KWD 21.00 High: KWD 31.00
ربحية السهم المستقبلية
-KWD 1.35
الإيرادات المقدّرة
56.74M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 1.38
KWD 0.72 – KWD 3.08
959.66M 5
FY2029 KWD 0.03
KWD 0.02 – KWD 0.06
579.19M 2
FY2028 -KWD 0.97
-KWD 2.00 – KWD 0.17
264.18M 7

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-05 -KWD 0.32 -KWD 0.29 +9.6%
2025-11-04 -KWD 0.39 -KWD 0.37 +5.1%
2025-08-05 -KWD 0.35 -KWD 0.39 -11.4%
2025-05-05 -KWD 0.29 -KWD 0.37 -27.6%
2025-03-03 -KWD 0.24 -KWD 0.29 -20.8%
2024-11-14 -KWD 0.23 -KWD 0.26 -13.0%
2024-08-07 -KWD 0.22 -KWD 0.24 -9.1%
2024-05-07 -KWD 0.18 -KWD 0.24 -33.3%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 4.46% annually over 5 years — modest growth
Debt/Equity of 0.12 — conservative balance sheet
Negative free cash flow of -216.89M
Revenue growth is decelerating — 1Y growth trails 5Y average by 23.13%

النمو

Revenue Growth (5Y)
4.46%
Revenue (1Y)-18.67%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-54.85%
ROIC-27.59%
Net Margin-513.17%
Op. Margin-521.04%

الأمان

Debt / Equity
0.12
Current Ratio15.39
Interest Coverage-22.82

التقييم

P/E Ratio
-6.82
Forward P/EN/A
P/B Ratio2.77
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -18.67% Revenue Growth (3Y) -5.83%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 4.46% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 51.82M Net Income (TTM) -265.94M
ROE -54.85% ROA -32.91%
Gross Margin 87.31% Operating Margin -521.04%
Net Margin -513.17% Free Cash Flow (TTM) -216.89M
ROIC -27.59% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.12 Current Ratio 15.39
Interest Coverage -22.82
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6.82 Forward P/E N/A
P/B Ratio 2.77 P/S Ratio 34.99
PEG Ratio -0.52 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 31.96 Fwd Earnings Yield N/A
FCF Yield -11.96%
Market Cap 1.81B Enterprise Value 1.16B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 51.82M 63.72M 58.44M 51.49M 43.52M
Net Income -265.94M -193.51M -80.74M -71.04M -6.55M
EPS (Diluted) -1.42 -1.22 -1.02 -0.97 -0.98
Gross Profit 45.25M 58.10M 53.16M 46.95M 39.12M
Operating Income -270.02M -171.78M -82.38M -78.65M -78.04M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 808.06M 457.94M 252.06M 149.29M 204.89M
Total Liabilities 153.75M 142.59M 160.93M 113.91M 116.89M
Shareholders' Equity 654.31M 315.34M 91.13M 35.38M 88.00M
Total Debt 79.78M 75.78M 83.39M 64.28M 58.98M
Cash & Equivalents 737.06M 392.10M 195.81M 102.30M 164.16M
Current Assets 782.13M 440.99M 232.24M 129.63M 191.30M
Current Liabilities 50.81M 41.35M 34.90M 31.40M 26.34M